Letter to Editor

Metabolic Wellbeing and Covid–19

Carmine Finelli1,2*

1Department of Internal Medicine, Ospedale Cav. R. Apicella, ASL Napoli 3 Sud, Via di Massa, 1, 80040 Pollena (Napoli), Italy
2Covid Hospital Boscotrecase, ASL Napoli 3 Sud, Via Lenza, 3, 80042 Boscotrecase (Napoli), Italy

Received: 15 August, 2020
Accepted: 04 November, 2020
Published: 05 November, 2020

*Corresponding author: Carmine Finelli, MD, PhD, Department of Internal Medicine, Ospedale Cav. R. Apicella – ASL Napoli 3 Sud, Via di Massa, 1, 80040 Pollena (Napoli), Italy, E-mail: CarmineFinelli74@yahoo.it

Keywords: Metabolic wellbeing; Metabolic syndrome; SARS-CoV-2; Type 2 diabetes mellitus; COVID-19

Abstract

The effects of infection with SARS-CoV-2 on host health are complex and major differences in the severity of the disease are observed. The best choices, nevertheless, are prevention and management. The main functions of genomic metabolic processes regulated by various physiological mechanisms are defined by the metabolic health of a person. Disordered genomic metabolic processes and a reduction in metabolic health are triggered by disruption of these mechanisms. Weaknesses health is the main risk factor for extreme COVID-19. It is probable that potential physiological changes induced by metabolic syndrome and T2D will overlap with COVID-19, potentially exacerbating the course of the disease. Although chronic diabetes hyperglycaemia contributes to harm that can exacerbate the path of the disease in COVID-19, recent research indicates that in patients with COVID-19 and T2D, dysregulated glucose by itself is counterproductive. To regulate the host inflammatory response, to reduce tissue susceptibility to inflammatory damage signals and to maintain physiological function during the extreme and critical phase of infection, glycaemic control is essential.

Introduction

The effects of infection with SARS–CoV–2 on host health are complex and major differences in the severity of the disease are observed. It is possible to identify COVID–19 cases as either asymptomatic or symptomatic. For 40–45 percent of infected persons, asymptomatic persons include carriers who test positive for SARS–CoV–2 and display no symptoms, such as those who test negative for the virus but display seroconversion suggesting a previous infection without ever showing symptoms [1]. These individuals maintain their wellbeing over time during infection, displaying a phenotype of improving health [2]. Symptomatic people include those with no symptoms who exhibit illness after a presymptomatic period. It is very difficult to distinguish between true asymptomatic and pre–symptomatic states. Asymptomatic people are identified as persons that test positive for RT–PCR but lack symptoms that would suggest infection with SARS–CoV–2 [3]. Although some people may go through the whole infection course and never experience symptoms, days or weeks later, some people who initially present as asymptomatic may begin to develop symptoms [3]. The people who will experience symptoms later are described as being presymptomatic. Around 80% of these individuals have a ‘mild’ course of illness, while the other 20% proceed to serious and severe conditions correlated with respiratory failure, Acute Respiratory Distress Syndrome (ARDS) and pneumonia, septic shock and multi–organ failure [4].

The clinical manifestations can be split into three phases for symptomatic individuals. When a person becomes symptomatic, phase 1 begins. Usually, individuals experience a dry cough and fever, and they can lose their taste and smell senses, and feel general malaise. The infection is restricted to this phase for most individuals, with sufficient self-care [5]. The pulmonary phase of the infection is identified in phase 2. Pulmonary inflammation and pneumonia occur in individuals who reach this stage, either without hypoxia or with hypoxia [5]. Those individuals need hospitalization. Mechanical ventilation is usually needed for patients with prolonged hypoxia [5]. Then, patients can advance to phase 3. ARDS and extrapulmonary systemic hyperinflammation syndrome may emerge in these patients who are in severe situation. Furthermore, shock, vasoplegia, respiratory failure, cardiopulmonary collapse, myocarditis, acute kidney injury, and other extrapulmonary complications may grow [5]. For most of these patients, the prognosis is negative, and some begin to drop towards death, while others reach stage 4, the period of recovery, and survive and show a phenotype of healthy resistance [6].
The best choices, nevertheless, are prevention and management [7]. It was examined that, based on the situation and symptoms of the patient, a mixture of antiviral drugs with hydroxychloroquine and azithromycin (with a medical practitioner’s consultation) could be the best choice to treat the patients [7]. It is urgently advised and demanded that the preventive steps, management and quarantine should be strictly followed by all individuals without any religious disparity, otherwise the situation could be the worst [7].

**Metabolic processes and physiological mechanisms**

The main functions of genomic metabolic processes regulated by various physiological mechanisms are defined by the metabolic health of a person. Disordered genomic metabolic processes and a reduction in metabolic health are triggered by disruption of these mechanisms. Weaknesses in metabolic health is the main risk factor for extreme COVID-19. T2D is among the most popular co-morbidities in infected people in reported coronavirus infections [8,9]. T2D, obesity and hypertension tend to be significant comorbidities in people with COVID-19 in line with this observation, and are associated with more serious and essential courses of COVID-19 disease [10–12]. It is possible that the reasons for this result are multi-factual and are traditionally assumed to include immune dysfunction. In particular, for instance, people with metabolic syndrome and T2D have impaired immune function, and their antiviral response to SARS-CoV-2 could also be impaired [12]. In addition, physiological complications of T2D and metabolic syndrome are also likely to play a synergistic role in the pathophysiology of SARS-CoV-2, rendering patients more vulnerable, regardless of viral strain, to the development of extreme pathology. Additionally, young obese individuals tend to need hospitalization and to contract more serious and important diseases among people with COVID-19 in the world [13]. This finding indicates that in young people, obesity can move COVID-19 towards more serious and important conditions. One potential reason may be that by obstructing diaphragm excursion, obesity imposes physical stress on breathing. In addition, the risk of pulmonary fibrosis, chronic obstructive pulmonary disease and decreased respiratory function is increased by diabetes. These disorders further exacerbate the breathing and hypoxic conditions of patients, contributing to multi-organ injury, as patients with COVID-19 advance to the pulmonary stages of the disease and produce pneumonia and ARDS.

It is probable that potential physiological changes induced by metabolic syndrome and T2D will overcap with COVID-19, potentially exacerbating the course of the disease. Chronic inflammatory conditions include T2D and metabolic syndrome. The increased underlying inflammatory state in patients with pre-existing impaired metabolic health may raise the danger that the immune process will exceed pathogenic stages, as well as the risk of physiological damage, since the extreme and important phases of COVID-19 are guided by an increased immune response to inflammation (cytokine storm) [12]. Likewise, risk factors for kidney failure are diabetes and hypertension together. Diabetes progresses to diabetic kidney disease, in which a reduction in the function of the kidney results in the accumulation of toxic metabolites that could really damage multiple organs [14,15]. The harm caused by hypertension to the blood vessels reduces the flow of blood to the kidneys and ultimately results in kidney injury. The kidney suffering inflicted by these currently existing metabolic conditions can make the kidneys more vulnerable to illness during SARS-CoV-2 infection, since kidney injury is a frequent cause of COVID-19 [16].

The risk of stroke and cardiovascular complications, which are also found in serious and important cases of COVID-19, is increased by obesity, diabetes and hypertension [17,18]. The blood vessels are weakened by prolonged hyperglycaemia and obesity and are possible causes for plaque buildup, which is itself necessary to induce blood clots. Individuals with COVID-19 have an increased coagulation reaction, which could increase the risk of stroke or pulmonary embolism in conjunction with pre-existing weakened blood vessels with plaques. The impact on the blood vessels of obesity and diabetes could contribute to hypertension, which in turn increases haemodynamics and changes the heart structure. This change will make the heart more vulnerable to damage related to the inflammatory response of the host, ARDS–induced hypoxia, virus infection of the heart, or other cardiac effects in response to extrapulmonary multi-organ damage, thereby potentially explaining why some patients with COVID-19 display signs of heart damage and heart attack. After this, in persons with diabetes, damage to blood vessels and nerves in the brain can cause vascular cognitive decline, dementia and stroke. Seizures are also caused by dysregulated glycaemia in diabetics. There are also factors that have a detrimental effect on brain health [19].

In the pathogenesis of these diseases, the prevalence of hypertension, cardiovascular disease, nephropathy and retinopathy in people with diabetes has impaired the renin-angiotensin system (RAS). Angiotensin II, the active metabolite of RAS and a potent vasoconstrictor that enhances vascular peripheral resistance, also induces insulin resistance and controls the absorption of sodium in the kidneys. Angiotensin-converting enzyme 2 (ACE2), a receptor that regulates the entry into host cells of SARS-CoV-2, antagonizes the actions of vasodilation-inducing angiotensin II. ACE2 expression in several target tissues of SARS-CoV-2 is increased in patients with T2D [20], and this enhancement has been suggested to be an adaptive mechanism that defends the body against diabetes–related physiological dysfunction [21]. This increased expression will boost the entry and resulting replication of SARS-CoV-2, as well as its distribution throughout the body in T2D patients. Thus, in the sense of COVID-19, a physiological defence technique used to promote metabolic health in T2D could be deleterious.

**Conclusions**

Although chronic diabetes hyperglycaemia contributes to harm that can exacerbate the path of the disease in COVID-19,
recent research indicates that in patients with COVID-19 and T2D, dysregulated glucose by itself is counterproductive. To regulate the host inflammatory response, to reduce tissue susceptibility to inflammatory damage signals and to maintain physiological function during the extreme and critical phase of infection, glycaemic control is essential. Therefore, in addition to providing to recognizing the pathophysiology of COVID-19 and how inadequate metabolic health exposes patients to a more serious course of disease, it could help to manipulate organismal metabolic variables in patients to shift the symptoms of a disease to a more desirable one, but in addition with other treatment mechanisms. After all, prevention and management seem to be the best solutions.

References

1. Oran DP, Topol EJ (2020) Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. Ann Intern Med 173: 362-367. Link: https://bit.ly/3oZv4AS
2. Tan J, Liu S, Zhuang L, Chen L, Dong M, et al. (2020) Transmission and clinical characteristics of asymptomatic patients with SARS-CoV-2 infection. Future Virol 15. Link: https://bit.ly/38aLekQ
3. Savvides C, Siegel R (2020) Asymptomatic and presymptomatic transmission of SARS-CoV-2: A systematic review. Preprint. medRxiv. Link: https://bit.ly/2HZOZyy
4. Yuki K, Fujiogi M, Koutsogiannaki S (2020) COVID-19 pathophysiology: A review. Clin Immunol 215: 108427. Link: https://bit.ly/3i2YDjW
5. Siddiqi HK, Mehra MR (2020) COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 39: 405-407. Link: https://bit.ly/38iMna2
6. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, et al. (2020) Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 323: 2052-2059. Link: https://bit.ly/363WwVD
7. Ali I, Alharbi OML (2020) COVID-19: Disease, management, treatment, and social impact. Sci Total Environ 728: 138861. Link: https://bit.ly/3s6Q0Qe
8. Wang X, Liu Z, Li J, Zhang J, Tian S, et al. (2020) Impacts of Type 2 Diabetes on Disease Severity, Therapeutic Effect, and Mortality of Patients With COVID-19. J Clin Endocrinol Metab 105: dgaa535. Link: https://bit.ly/3mp7B3g
9. Lampasona V, Secchi M, Scavini M, Bazzigaluppi E, Brigatti C, et al. (2020) Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia 1-11. Link: https://bit.ly/3enYunf
10. Finelli C (2019) Metabolic Syndrome and Adipose Tissue: Potential Connections. EC Endocrinology and Metabolic Research 35-37. Link: https://bit.ly/34W5QLx
11. Finelli C (2020) Metabolic Syndrome and COVID 19: Current Condition! EC Endocrinology and Metabolic Research 5: 01-02.
12. Finelli C (2020) Obesity, COVID-19 and immunotherapy: the complex relationship. Immunotherapy 12: 1105-1109.
13. Clemmensen C, Petersen MB, Sørensen TIÁ (2020) Will the COVID-19 pandemic worsen the obesity epidemic?. Nat Rev Endocrinol 16: 469-470. Link: https://bit.ly/2JvhrC5
14. Roy A, Maili A, Sinha A, Baidya A, Basu AK, et al. (2020) Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement. Diabetes Ther. Link: https://bit.ly/3oYCLXJ
15. Cheng Y, Shang J, Liu D, Xiao J, Zhao Z (2020) Development and validation of a predictive model for the progression of diabetic kidney disease to kidney failure. Ren Fail 42: 550-559. Link: https://bit.ly/3erjzv4
16. Ajaym M, Melamed ML (2020) COVID-19 in Patients with Kidney Disease. Clin J Am Soc Nephrol 15: 1087-1089. Link: https://bit.ly/34WstYCJ
17. Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, et al. (2020) Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry. Stroke 51: e254-e258. Link: https://bit.ly/2i3RmAd
18. Robinson FA, Mhealsick RP, Wagener BM, Hanna P, Poston MD, et al. (2020) Role of angiotensin converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection. Am J Physiol Heart Circ Physiol. Link: https://bit.ly/3epKdU8
19. Nikbakht F, MohammadkhaniZadeh A, Mohammad E (2020) How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms. Mult Scier Relat Disord 46: 102535. Link: https://bit.ly/2I6wVsT
20. Wijnant SR, Jacobs M, Van Eckhoutte HP, Lapauw B, Joos GF et al. (2020) Expression of ACE2, the SARS-CoV-2 Receptor, in Lung Tissue of Patients With Type 2 Diabetes. Diabetes 2020; db200669. Link: https://bit.ly/2T0rgDk
21. Wu J, Deng W, Li S, Yang X (2020) Advances in research on ACE2 as a receptor for 2019-nCoV. Cell Mol Life Sci 1-14. Link: https://bit.ly/3jW3qku